GO:0030249 guanylate cyclase regulator activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030249 (guanylate cyclase regulator activity) is a molecular function that modulates the activity of guanylate cyclase enzymes, which convert GTP to the second messenger cGMP.
• Regulators include endogenous proteins such as Na+/H+ exchanger regulatory factor 4 (NHERF4), which suppresses guanylate cyclase 2C (GUCY2C) activity, and small molecules like carnosine that modulate soluble guanylate cyclase.
• Soluble guanylate cyclase (sGC) requires both alpha and beta subunits for catalytic activity, and its regulation is critical for nitric oxide signaling.
• Dysregulation of guanylate cyclase regulation is implicated in cardiovascular diseases, diarrhea, and intestinal pathophysiology [1,5,6].
• Studying GO:0030249 requires tools such as knockout and knock-in cell models, biochemical assays, and CRISPR screening to dissect regulator function [1,5].
• The coiled-coil domain of sGC is essential for allosteric regulation, highlighting structural determinants of regulator activity.
Description
Guanylate cyclase regulator activity (GO:0030249) is a molecular function that governs the activity of guanylate cyclases, the enzymes responsible for synthesizing cyclic GMP (cGMP) from GTP. This regulatory activity is essential for fine-tuning cGMP signaling, which controls diverse physiological processes including smooth muscle relaxation, neurotransmission, and intestinal fluid homeostasis [1,6]. Because cGMP is a key second messenger, its production must be tightly regulated; proteins and small molecules that modulate guanylate cyclase activity are therefore central to both normal physiology and disease [1,3]. Researchers study GO:0030249 to understand how cGMP levels are controlled and to identify therapeutic targets for conditions such as hypertension, heart failure, and secretory diarrhea [1,5]. The term encompasses both positive and negative regulators, including endogenous proteins like NHERF4 and small molecules such as carnosine [3,5]. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of guanylate cyclase regulator activity, its mechanisms, key genes, and experimental approaches.
guanylate cyclase regulator activity At A Glance
| GO ID | GO:0030249 |
|---|---|
| GO term | guanylate cyclase regulator activity |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Modulates the activity of guanylate cyclase enzymes, thereby influencing cGMP signaling. |
| Example regulators | NHERF4 (suppresses GUCY2C); carnosine (regulates soluble guanylate cyclase). |
| Associated enzymes | Soluble guanylate cyclase (sGC, heterodimer of alpha and beta subunits); transmembrane guanylate cyclase 2C (GUCY2C). |
| Disease relevance | Cardiovascular disease, diarrhea, intestinal pathophysiology [1,5,6]. |
| Research methods | Biochemical activity assays, knockout/knock-in models, CRISPR screening [1,5]. |
What Is GO:0030249?
According to the Gene Ontology, GO:0030249 (guanylate cyclase regulator activity) is defined as any molecular function that modulates the activity of a guanylate cyclase enzyme. This includes proteins or other molecules that enhance or inhibit the catalytic conversion of GTP to cGMP by guanylate cyclases. The term is classified under molecular_function and does not have synonyms in the current ontology.
Why Is guanylate cyclase regulator activity Important in Cell Biology?
Guanylate cyclase regulator activity is critical because it controls the production of cGMP, a second messenger that regulates vascular tone, platelet aggregation, intestinal secretion, and neuronal signaling. Dysregulation of this activity contributes to hypertension, heart failure, and diarrheal diseases [1,5]. Understanding GO:0030249 provides mechanistic insights into how cGMP levels are maintained and offers opportunities for therapeutic intervention, such as sGC stimulators and activators used in cardiovascular medicine.
• Controls cGMP synthesis, a key second messenger in cardiovascular and gastrointestinal systems.
• Regulates smooth muscle relaxation and blood pressure.
• Modulates intestinal fluid secretion; dysregulation leads to diarrhea [5,6].
• Involved in platelet function and thrombosis.
• Target for drugs like sGC stimulators (riociguat) and activators.
• Endogenous regulators like NHERF4 provide insight into enterotoxin-triggered diarrhea.
• Carnosine acts as a regulator of soluble guanylate cyclase, linking metabolism to cGMP.
• Structural studies of sGC reveal allosteric regulation mechanisms.
• Both subunits of sGC are required for activity, highlighting complex regulation.
• Guanylate cyclase receptor family members are involved in diverse physiological processes.
Molecular Mechanism of guanylate cyclase regulator activity
Regulation of soluble guanylate cyclase (sGC) by endogenous factors
In simple terms: Soluble guanylate cyclase is turned on by nitric oxide, but other molecules can fine-tune its activity.
Soluble guanylate cyclase (sGC) is a heterodimeric enzyme that requires both alpha and beta subunits for catalytic activity. Its activity is primarily stimulated by nitric oxide (NO), which binds to the heme domain of the beta subunit, triggering a conformational change that activates the catalytic domain. Regulators of sGC activity include small molecules like carnosine, which has been shown to modulate sGC in biochemical assays. Additionally, the coiled-coil domain of sGC plays a critical role in allosteric regulation, as mutations in this domain affect enzyme activity. These regulatory mechanisms ensure that cGMP production is tightly controlled in response to physiological signals.
Suppression of transmembrane guanylate cyclase 2C (GUCY2C) by NHERF4
In simple terms: A protein called NHERF4 can put the brakes on a gut enzyme that makes cGMP, affecting fluid balance.
Transmembrane guanylate cyclase 2C (GUCY2C) is expressed in intestinal epithelial cells and regulates fluid and electrolyte balance. Recent studies have identified Na+/H+ exchanger regulatory factor 4 (NHERF4) as a negative regulator of GUCY2C. Specifically, the catalytic region mimetic of NHERF4 suppresses GUCY2C activity, thereby regulating enterotoxin-triggered diarrhea. This regulation is critical because excessive GUCY2C activity leads to secretory diarrhea, while its inhibition can reduce fluid loss. Thus, NHERF4 represents a key regulator of guanylate cyclase activity in the gut.
Allosteric regulation via the coiled-coil domain of sGC
In simple terms: The shape of the sGC enzyme can change to alter its activity, and a specific domain acts like a hinge.
The coiled-coil domain of soluble guanylate cyclase is essential for allosteric regulation. Wittenborn et al. (2023) demonstrated that mutations in this domain affect the enzyme's ability to transition between inactive and active states. This domain mediates subunit interactions and transmits conformational changes induced by NO binding to the catalytic site. Understanding these structural dynamics provides insight into how regulators might modulate sGC activity beyond traditional NO signaling.
Small molecule regulators: carnosine and beyond
In simple terms: Some small molecules, like carnosine, can directly influence guanylate cyclase activity.
Carnosine, a naturally occurring dipeptide, has been shown to regulate soluble guanylate cyclase activity in vitro. Severina et al. (2000) reported that carnosine modulates sGC, possibly by interacting with the heme moiety or affecting enzyme conformation. This finding highlights that guanylate cyclase regulator activity is not limited to proteins; small metabolites can also play a role. Such regulators may have therapeutic potential in conditions where cGMP signaling is impaired.
Guanylate cyclase receptor family and regulatory diversity
In simple terms: There are many types of guanylate cyclases, and each can be regulated differently.
The guanylate cyclase receptor family includes both soluble and transmembrane forms, each with distinct regulatory mechanisms. For example, transmembrane guanylate cyclases are activated by extracellular ligands such as natriuretic peptides or enterotoxins, while soluble guanylate cyclases respond to NO [2,6]. Regulators of these enzymes can act at various levels, including ligand binding, subunit assembly, and catalytic activity. This diversity underscores the importance of GO:0030249 in integrating multiple signals into cGMP production.
Key Genes Involved in GO:0030249 guanylate cyclase regulator activity
The following genes and proteins are key players in guanylate cyclase regulator activity, either as regulators or as the guanylate cyclases themselves.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GUCY1A1 | Alpha subunit of soluble guanylate cyclase | Required for catalytic activity; target for sGC stimulators. |
| GUCY1B1 | Beta subunit of soluble guanylate cyclase | Contains heme domain for NO binding; essential for activity. |
| GUCY2C | Transmembrane guanylate cyclase 2C | Regulates intestinal fluid balance; target of NHERF4 [5,6]. |
| NHERF4 | Suppresses GUCY2C activity | Catalytic region mimetic inhibits GUCY2C, reducing diarrhea. |
| Carnosine | Small molecule regulator of sGC | Modulates sGC activity in vitro. |
| NPR1 | Natruiretic peptide receptor 1 (guanylate cyclase A) | Transmembrane guanylate cyclase activated by ANP. |
| NPR2 | Natruiretic peptide receptor 2 (guanylate cyclase B) | Activated by CNP; involved in bone growth. |
| GUCY2D | Retinal guanylate cyclase 1 | Mutations cause Leber congenital amaurosis. |
| GUCY2F | Retinal guanylate cyclase 2 | Involved in phototransduction. |
| HSP90 | Chaperone for sGC | Assists in sGC maturation and regulation. |
| NO | Nitric oxide | Primary activator of sGC. |
| cGMP | Cyclic GMP | Product of guanylate cyclase; second messenger. |
| PKG | cGMP-dependent protein kinase | Downstream effector of cGMP. |
| PDE5 | Phosphodiesterase 5 | Degrades cGMP; indirect regulator. |
| sGC stimulators | Small molecules (e.g., riociguat) | Enhance sGC activity independent of NO. |
| sGC activators | Small molecules (e.g., cinaciguat) | Activate sGC when heme is oxidized. |
| ANP | Atrial natriuretic peptide | Ligand for NPR1. |
| CNP | C-type natriuretic peptide | Ligand for NPR2. |
How Is guanylate cyclase regulator activity Regulated?
Guanylate cyclase regulator activity is itself regulated at multiple levels. The expression and stability of guanylate cyclases are controlled by transcriptional and post-translational mechanisms. For sGC, the availability of heme and the chaperone HSP90 are critical for proper folding and activity. Allosteric regulation via the coiled-coil domain modulates the enzyme's responsiveness to NO. Additionally, endogenous inhibitors like NHERF4 can suppress GUCY2C activity in a context-dependent manner. Small molecules such as carnosine can directly influence sGC activity. These regulatory layers ensure that cGMP production is finely tuned to physiological needs.
guanylate cyclase regulator activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GUCY1A1/GUCY1B1 | Hypertension, heart failure | Knockout mice, sGC stimulator treatment. |
| GUCY2C | Secretory diarrhea, intestinal inflammation | Intestinal epithelial cell lines, knockout mice [5,6]. |
| NHERF4 | Enterotoxin-triggered diarrhea | Knockdown in Caco-2 cells, knockout mice. |
| GUCY2D | Leber congenital amaurosis | Retinal organoids, knock-in mice. |
| NPR1 | Cardiovascular disorders | Knockout mice, overexpression models. |
Cardiovascular diseases
Impaired guanylate cyclase regulation leads to reduced cGMP signaling, contributing to hypertension, heart failure, and pulmonary hypertension. sGC stimulators and activators are used clinically to enhance cGMP production when endogenous regulation is defective. For example, riociguat stimulates sGC independently of NO, improving outcomes in pulmonary arterial hypertension.
Intestinal pathophysiology and diarrhea
GUCY2C is a key regulator of intestinal fluid secretion. Excessive activation by bacterial enterotoxins causes secretory diarrhea. NHERF4 acts as a negative regulator of GUCY2C, and its catalytic region mimetic suppresses GUCY2C activity, offering a potential therapeutic strategy for diarrhea. Dysregulation of this pathway is also implicated in inflammatory bowel diseases.
Retinal degenerations
Mutations in retinal guanylate cyclases (GUCY2D, GUCY2F) disrupt cGMP homeostasis in photoreceptors, leading to Leber congenital amaurosis and other retinal dystrophies. Regulators of these enzymes are therefore potential targets for gene therapy.
From guanylate cyclase regulator activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate guanylate cyclase activity? | Knockout cell line (e.g., HEK293) with sGC reporter. |
| What is the effect of a point mutation in sGC on regulation? | Point-mutation knock-in via CRISPR. |
| Can a candidate regulator be tagged for localization? | Tagged knock-in (e.g., GFP). |
| Does overexpression of NHERF4 suppress GUCY2C? | Overexpression cell model. |
| Which genes modulate cGMP levels? | CRISPR library screening with cGMP biosensor. |
| How does carnosine affect sGC activity? | In vitro biochemical assay with purified sGC. |
How to Study the guanylate cyclase regulator activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Guanylate cyclase activity assay | Conversion of GTP to cGMP | Testing regulator effects in vitro. |
| CRISPR knockout | Loss-of-function phenotype | Identifying essential regulators. |
| CRISPR knock-in | Point mutations or tags | Structure-function studies. |
| cGMP biosensor imaging | Real-time cGMP levels | Live-cell dynamics. |
| CRISPR library screening | Genome-wide regulator identification | Discovery of novel regulators. |
| Western blot | Protein expression | Validating knockout/overexpression. |
| Co-immunoprecipitation | Protein-protein interactions | Identifying regulator complexes. |
| Mass spectrometry | cGMP quantification | Biochemical assays. |
Biochemical activity assays
Guanylate cyclase activity is typically measured by monitoring the conversion of GTP to cGMP using radioimmunoassays or mass spectrometry. These assays can be used to test the effect of candidate regulators such as carnosine or NHERF4 [3,5].
CRISPR knockout and knock-in models
CRISPR-Cas9 can generate knockout cell lines for guanylate cyclase genes or their regulators to assess loss-of-function phenotypes. Knock-in of point mutations (e.g., in the coiled-coil domain of sGC) allows structure-function studies.
cGMP biosensors and imaging
Genetically encoded cGMP biosensors (e.g., cGES-DE5) enable real-time monitoring of cGMP dynamics in live cells. These tools are valuable for studying how regulators affect cGMP levels spatially and temporally.
CRISPR library screening
Genome-wide CRISPR screens coupled with a cGMP-dependent reporter can identify novel regulators of guanylate cyclase activity. This approach has been used to discover genes affecting cGMP signaling in various cell types.
How CRISPR Can Be Used to Study GO:0030249 guanylate cyclase regulator activity
Knockout
CRISPR knockout of guanylate cyclase genes (e.g., GUCY1A1, GUCY1B1) or their regulators (e.g., NHERF4) can reveal their role in cGMP signaling [1,5]. For example, knockout of GUCY2C in intestinal cells abolishes enterotoxin-induced cGMP production.
Point Mutation
Point mutations in the coiled-coil domain of sGC can be introduced via CRISPR to study allosteric regulation. Such models help dissect the molecular determinants of regulator activity.
Knock-in
Knock-in of tagged versions of guanylate cyclases or regulators (e.g., GFP-NHERF4) allows visualization and interaction studies. This approach is useful for tracking protein localization and dynamics.
Overexpression
Overexpression of candidate regulators (e.g., NHERF4) in cell lines can test their ability to suppress or enhance guanylate cyclase activity. This is particularly useful for validating negative regulators.
How EDITGENE Supports guanylate cyclase regulator activity Research
Researchers studying guanylate cyclase regulator activity-related genes often need to determine whether a candidate gene is causally involved in cGMP signaling. EDITGENE provides comprehensive CRISPR-based services to accelerate this research, from knockout and point-mutation models to library screening and bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for guanylate cyclase regulator activity research.
Frequently Asked Questions About guanylate cyclase regulator activity
What is guanylate cyclase regulator activity?
It is a molecular function (GO:0030249) that modulates the activity of guanylate cyclase enzymes, which produce cGMP.
What genes are involved in guanylate cyclase regulator activity?
Key genes include GUCY1A1, GUCY1B1, GUCY2C, and NHERF4, among others [5,7].
How is guanylate cyclase activity regulated?
It is regulated by nitric oxide, endogenous proteins like NHERF4, small molecules like carnosine, and allosteric mechanisms [1,3,5,8].
What diseases are associated with guanylate cyclase regulator activity?
Cardiovascular diseases, secretory diarrhea, and retinal degenerations [1,2,5,6].
What is the role of NHERF4 in guanylate cyclase regulation?
NHERF4 suppresses GUCY2C activity, thereby regulating enterotoxin-triggered diarrhea.
How can I study guanylate cyclase regulator activity?
Using biochemical assays, CRISPR knockout/knock-in models, cGMP biosensors, and CRISPR screening [1,5].
What is soluble guanylate cyclase?
A heterodimeric enzyme that produces cGMP in response to nitric oxide [4,7].
What is GUCY2C?
A transmembrane guanylate cyclase that regulates intestinal fluid balance and is a target in diarrhea.
Can carnosine regulate guanylate cyclase?
Yes, carnosine has been shown to modulate soluble guanylate cyclase activity.
What CRISPR models are available for guanylate cyclase research?
Knockout, point mutation, knock-in, and overexpression models, as well as library screening [1,5].
Conclusion
Guanylate cyclase regulator activity (GO:0030249) is a critical molecular function that controls cGMP signaling, impacting cardiovascular, gastrointestinal, and retinal physiology. Understanding its mechanisms and key regulators like NHERF4 and sGC subunits offers therapeutic opportunities. EDITGENE provides comprehensive CRISPR services to study these regulators and accelerate drug discovery.
References
- 1. Grześk G et al.. 2021. Current Modulation of Guanylate Cyclase Pathway Activity-Mechanism and Clinical Implications.. Molecules 26(11) PMID: 34200064
- 2. Garbers DL. 1990. Guanylate cyclase receptor family.. Recent Prog Horm Res 46:85-96; discussion 96-7 PMID: 1980749
- 3. Severina IS et al.. 2000. Carnosine as a regulator of soluble guanylate cyclase.. Biochemistry (Mosc) 65(7):783-8 PMID: 10951096
- 4. Poulos TL. 2006. Soluble guanylate cyclase.. Curr Opin Struct Biol 16(6):736-43 PMID: 17015012
- 5. Ramananda Y et al.. 2025. Catalytic region mimetics in Na+/H+ exchanger regulatory factor 4 suppress guanylate cyclase 2C activity to regulate enterotoxin triggered diarrhea.. J Biol Chem 301(10):110559 PMID: 40759370
- 6. Steinbrecher KA et al.. 2011. Transmembrane guanylate cyclase in intestinal pathophysiology.. Curr Opin Gastroenterol 27(2):139-45 PMID: 21102322
- 7. Buechler WA et al.. 1991. Expression of soluble guanylate cyclase activity requires both enzyme subunits.. Biochem Biophys Res Commun 174(1):351-7 PMID: 1671207
- 8. Wittenborn EC et al.. 2023. Role of the Coiled-Coil Domain in Allosteric Activity Regulation in Soluble Guanylate Cyclase.. Biochemistry 62(10):1568-1576 PMID: 37129924
